Abstract: Methods and compositions for the downregulation of P2X7 receptor expression or activity are disclosed. Preferred compositions comprise siNA. The methods and compositions are useful in the treatment of diseases characterised by increased 112X7 receptor activity, such as neuronal degeneration, Alzheimer's disease, inflammatory diseases, and some cancers.
Type:
Application
Filed:
August 30, 2005
Publication date:
October 22, 2009
Applicant:
Sylentis S.A.
Inventors:
Ana I. Jimenez, Angela Sesto, Jose P. Roman, Irene Gascon, Gonzalo Gonzalez De Buitrago, Maria C. Jimenez
Abstract: Methods and compositions for the downregulation of P2X7 receptor expression or activity are disclosed. Preferred compositions comprise siNA. The methods and compositions are useful in the treatment of diseases characterised by increased 112X7 receptor activity, such as neuronal degeneration, Alzheimer's disease, inflammatory diseases, and some cancers.
Type:
Application
Filed:
August 30, 2005
Publication date:
January 1, 2009
Applicant:
Sylentis S.A.
Inventors:
Ana I. Jimenez, Angela Sesto, Jose P. Roman, Irene Gascon, Gonzalo Gonzalez De Buitrago, Maria C. Jimenez
Abstract: Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.
Type:
Application
Filed:
August 23, 2005
Publication date:
November 22, 2007
Applicant:
Sylentis S.A.
Inventors:
Ana Jimenez, Angela Sesto, Jose Roman, Irene Gascon, Gonzalo Gonzalez de Buitrago
© 2025 Justia
